Abstract 369P
Background
Molecular profiling of tumour tissue to guide treatment of patients (pts) with advanced solid tumours has previously been reported. Most series were reported from large volume academic cancer centres in the West. There is a paucity of data reporting the experience and applicability of such an approach in Asia. We report our single-centre experience of conducting a prospective molecular profiling programme for pts in advanced solid tumours.
Methods
Pts with advanced solid tumours aged >/= 18 years, good performance status and archival tumour tissue available were prospectively consented. The RNA extracted from the FFPE tissue sections were subjected to RNA-sequencing using Archer FusionPlex Solid Tumor Kit and Archer Analysis Software 5.1. The putative gene translocations or alternative splicing were further confirmed with RT-PCR or FISH.
Results
253 pts consented between Feb 2017 and Feb 2019. Demographics: M:F 138 : 115; Median age = 58 (range: 19-89). Diseases included sarcomas (n = 88, 35%), NSCLC (n = 61, 24%), glioma (n = 42, 17%), melanoma (n = 7, 3%) and others (n = 55, 21%). Median turn-around time from consent to availability of report: 24 days (range: 3-112 days). 89% of samples passed quality control assessments. 8% (n = 21) of samples could not be processed due to insufficient material (n = 18), decalcified specimen (n = 2) and poor RNA quality (n = 1). 20 pts (9% of tested samples) had actionable genomic alterations identified that resulted in off-label use of directed anti-cancer therapies, referral to clinical trials or compassionate access programmes. These include EGFRvIII mutations (n = 7) and MET alterations (n = 2) in gliomas; ROS1 (n = 4), ALK (n = 2), MET exon 14-skipping (n = 1) and RET (n = 1) rearrangements in NSCLC; ALK rearranged sarcoma (n = 1). Across all diseases, 3 pts with NTRK fusions were identified.
Conclusions
We report the first institutional-based molecular profiling programme in Hong Kong. Such programmes are feasible in Asia. Pts can potentially benefit from identification of actionable alterations within a reasonable time frame and be channelled to appropriate therapies or clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Chinese University of Hong Kong.
Funding
F. Hoffmann-La Roche Ltd (formerly Ignyta Inc.).
Disclosure
H. Loong: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Advisory / Consultancy: Celgene; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Eli Lilly; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Sereno; Advisory / Consultancy, Speaker Bureau / Expert testimony: AbbVie; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Eisai; Speaker Bureau / Expert testimony: Guardant Health; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bayer; Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Sharp & Dohme; Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Takeda ; Research grant / Funding (institution): Mundipharma. B.B.Y. Ma: Speaker Bureau / Expert testimony: Roche. E.P. Hui: Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Speaker Bureau / Expert testimony: Merck Sereno; Advisory / Consultancy: Merck Sharp & Dohme; Research grant / Funding (institution): Merck Sharp & Dohme; Research grant / Funding (institution): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract